1. Biogen earnings + surprise news about Alzheimer’s drug aducanumab — Bristol-Myers makes Opdivo pitch for frontline lung cancer — Criticism of ProPublica’s latest analysis of physician payment data — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Beigene

Discussion in 'Biotech Startups' started by anonymous, May 15, 2019 at 11:45 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I am hearing that this company might be the next big thing. Anyone?
     
  2. anonymous

    anonymous Guest

    Chinese financing and marketing leads one to believe that they will be aggressive.
     
  3. anonymous

    anonymous Guest

    Fuck this company. It ain’t America
     
  4. anonymous

    anonymous Guest

     
  5. anonymous

    anonymous Guest

    When are they interviewing for managers??
     
  6. anonymous

    anonymous Guest

    now
     
  7. anonymous

    anonymous Guest

    heard from BD the rep positions will be posted within the next few weeks. i'm ready
     
  8. anonymous

    anonymous Guest

    Anyone know the equity offering? My concern is that they will not be a buyout candidate since they are a Chinese owned company and selling companies to non-Chinese is very difficult to do. As we know most of the wealth created in biotech is from buyouts so wondering what the upside potential is on this one?
     
  9. anonymous

    anonymous Guest

    Next big thing? I seriously doubt that. A lot of the data and trials with this company have been or are being done in China. Anyone that knows anything about the Chinese medical system and how the Chinese and government there conduct business there hould question the validity of clinical trials results coming out of China.

    Besides, AstraZeneca already has a big headstart in the less of target side effects vs. ibrutinib market. Zanibrutinib will be 3rd to market and offer nothing acalabrutinib and ibrutinib don't already.

    This company and stock are very overvalued. They may be aggressive because they have to be but that won't be enough. It may only get the company on the US government radar. A Chinese company is going to get a lot of scrutiny given the current environment regardless of how they market their products.
     
  10. anonymous

    anonymous Guest

    I see rep positions are posted. Anyone been contacted? If so, is the comp any good?
     
  11. anonymous

    anonymous Guest

    They hired RD ? Bwahaha. Good luck working for this guy.
     
  12. anonymous

    anonymous Guest

    Anyone know anything about the deal they're offering? Base? Co Car? etc.
     
  13. anonymous

    anonymous Guest

    No. It’s friends calling friends. You must not be a friend.
     
  14. anonymous

    anonymous Guest

    Any updates? Salary, car allowance, etc?
     
  15. anonymous

    anonymous Guest

    Seeking Alpha article just sepculated that they are cooking the books and they have made questionable puchases of realestate that may be a hidden bribe. Stock down 25 this week. Do your own DD and take a close look.
     
  16. anonymous

    anonymous Guest

    Thanks. I saw that Friday and have read the report and BeiGene’s responses. I’m still curious on the above though. Like any startup, it’s a risk. It mainly depends on what you are potentially leaving.
     
  17. anonymous

    anonymous Guest


    It is a Chinese company. Do your due diligence and ask yourselves is working for this type of company with questions already swirling about business practices and ethics really a good place to be.
     
  18. anonymous

    anonymous Guest

    Risk is one thing...an unsound business model and fraud? Very different.
     
  19. anonymous

    anonymous Guest

    Read the research report published on 9/6. Scary stuff and ran by crooks and Chinese which pretty much validated the accounting and shady dealings. Only a fool would join such fray.
     
  20. anonymous

    anonymous Guest

    hahahahaha the next big thing? All me-to 2nd or worst to market. Lots of ex- Genentech which will be over matched once they realize its a lot harder to sell drugs that aren't named rituximab, trastuzumab or bevacizumab. Will be hard to get any coverage in the USA, currently questionable financials and out laying a bunch of cash with little to no revenue coming in from drugs being marketed in China.

    More likely a great short sell opportunity. Look at the numerous companies in this thread- how many were supposed to 'be the next big thing" and how many are completely struggling. Pipeline is garbage and management is questionable at best. Unless you are currently at Genentech with little equity in your brand and will likely get cut I would stay away. Even if you are at Genentech and likely to get cut the severance and much talked about retention bonuses should be enough to more than make up the sign on RSU and little bump in pay from this dog.

    But I realize many of you aren't that good and don't have options. If that is the case hopefully you know the hiring managers at Beigene! Seattle Genetics will be hiring soon- much better than this place! You've been warned! Can't wait to quote this thread 1 year from now....